Wedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)

Key Points

• Wedbush analysts have revised their Q3 2025 EPS forecast for Pharvaris, improving it from ($0.87) to ($0.77), and maintain an "Outperform" rating with a price objective of $27.00.
• Pharvaris reported a Q3 earnings miss with an EPS of ($0.94), falling short of the consensus estimate of ($0.87) by $0.07.
• Several other analysts have adjusted their price targets for Pharvaris, with Cantor Fitzgerald lowering theirs from $28.00 to $25.00, indicating a trend of cautious sentiment around the stock.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Analysts at Wedbush increased their Q3 2025 EPS estimates for Pharvaris in a research report issued to clients and investors on Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($0.87). Wedbush has a "Outperform" rating and a $27.00 price objective on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.82) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at $0.73 EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07).

A number of other equities analysts have also recently issued reports on PHVS. Cantor Fitzgerald cut their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. JMP Securities reduced their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a research note on Wednesday. Finally, Guggenheim initiated coverage on shares of Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Pharvaris has an average rating of "Buy" and a consensus price target of $35.60.

Pharvaris Trading Up 7.3%

Pharvaris stock opened at $22.99 on Friday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -6.84 and a beta of -2.81. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33. The firm's fifty day moving average price is $19.60 and its two-hundred day moving average price is $17.21.

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently modified their holdings of the stock. Soleus Capital Management L.P. grew its position in Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after purchasing an additional 216,483 shares during the period. Octagon Capital Advisors LP lifted its stake in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after purchasing an additional 157,530 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after buying an additional 118,408 shares in the last quarter. Northern Trust Corp grew its position in Pharvaris by 483.9% during the fourth quarter. Northern Trust Corp now owns 91,932 shares of the company's stock valued at $1,762,000 after buying an additional 76,188 shares during the period. Finally, TFG Asset Management GP Ltd increased its holdings in Pharvaris by 48.1% in the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after buying an additional 61,105 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.